Inclusion Criteria:

          -  Patient must have histologically or cytologically documented evidence of prostate
             adenocarcinoma

          -  Patient must previously have undergone radical prostatectomy

          -  Patient must previously have undergone either adjuvant or salvage radiation therapy to
             the prostatic fossa +/- whole pelvis

          -  PSA doubling time must be calculated utilizing all PSA measurements from most recent
             biochemically-recurred (BCR). PSA doubling time must be > 3 months and < 18 months.
             The Memorial Sloan Kettering PSA doubling time calculator should be used

          -  Patient must have no previous evidence of radiographically detectable metastatic
             prostate cancer by conventional CT and bone scan imaging

          -  Patient must have total testosterone level > 120 ng/dL demonstrated within 28 days of
             enrollment

          -  Patient must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
             1

          -  Absolute neutrophil count (ANC) >= 1.0 X 10^9/L

          -  Platelet count >= 100 X 10^9/L

          -  Hemoglobin >= 9 g/dL

          -  Potassium >= 3.5

          -  Serum bilirubin =< 1.5 X upper limit of normal (ULN) or =< 3 X ULN for patients with
             documented Gilbert's syndrome

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 X ULN

          -  Creatinine clearance (Cr Cl) >= 30 mL/min as estimated by the Cockcroft-Gault criteria
             or as determined by 24 hour Cr Cl measurement

          -  Patient must be able to understand and authorize informed consent

        Exclusion Criteria:

          -  Chronic active hepatitis B or C

          -  History of a second, non-prostate malignancy that required systemic therapy in the
             last 2 years except cancer in situ of bladder and non-melanomatous cancers of the skin

          -  Patient with a serious underlying medical condition that would otherwise impair the
             patient's ability to undergo fluciclovine PET/CT imaging or receive subsequent
             treatment

          -  Any condition that would alter the patient's mental status, prohibiting understanding
             and/or authorization of informed consent

          -  Expected lifespan of less than 12 weeks

          -  Inability to lay still for imaging

          -  Weight > 300 lbs. (due to equipment specifications)

          -  Any other underlying medical condition that, in the opinion of the investigator, would
             impair the ability of the patient to receive or tolerate the planned treatment and/or
             follow up